Partnering

University of Maastricht / MUMC+

Matisse Pharmaceuticals BV has obtained a worldwide exclusive and transferable license from Maastricht University (MU) and Maastricht University Medical Centre (MUMC+) for commercializing M6229 and Next Generation M6229. The University of Maastricht is supporting Matisse in further research and pre-clinical activities.   

AUMC

Matisse Pharmaceuticals is working closely together with the Amsterdam University Medical Center where also the investigator driven Histoseps Phase I/IIa clinical dose escalation study with M6229 in septic patients in the Intensive Care Unit (ICU) took place. 

Basic Pharma

For the CMC part of the development, such as drug substance process development, galenic development, analytics, IMP manufacture and regulatory affairs, Matisse Pharmaceuticals can rely on the expertise and facilities offered by the Basic Pharma Group.

EpiDisease

EpiDisease is a biotechnology company based in Valencia, focused on the development of diagnostic solutions based on epigenetic biomarkers. Its mission is to advance personalized medicine through high-precision diagnostic tools. EpiDisease and Matisse have a joint program in place to revolutionize the treatment and diagnosis of sepsis by developing and validating Matisse’s M6229 therapy alongside the HistSHOCK IVD kit, to detect circulating histones in patients with sepsis.